﻿<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Cision News</title><link>https://news.cision.com</link><description>Cision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.</description><pubDate>Tue, 09 Jun 2026 12:41:50 GMT</pubDate><image><title>Cision News</title><width>146</width><height>60</height><link>https://news.cision.com</link><url>https://news.cision.com/Content/img/news-logo.png</url></image><item><title>VISCOGEL INITIATES PHASE I/II CLINICAL TRIAL FOR ITS NOVEL VACCINE ADJUVANT</title><link>http://news.cision.com/viscogel-ab/r/viscogel-initiates-phase-i-ii-clinical-trial-for-its-novel-vaccine-adjuvant,c9249778</link><guid isPermaLink="false">cision482981</guid><description><![CDATA[Viscogel AB today announced that dosing began in the Phase I/II clinical trial with ViscoGel®, a novel vaccine adjuvant based on the company's proprietary chitosan technology. ViscoGel® has been shown to be safe and effective in pre-clinical studies.
The first part of the Phase I/II trial is a single-ascending dose study with ViscoGel® in 30 healthy volunteers. The second part is a single-dose study in 100 healthy volunteers where ViscoGel® is dosed in combination with a commercially available prophylactic vaccine to evaluate safety and efficacy. The trial is performed at Karolinska Trial]]></description><pubDate>Mon, 23 Apr 2012 09:42:37 GMT</pubDate></item><item><title>VISCOGEL AB REPORTS POSITIVE RESULTS FROM SAFETY STUDIES</title><link>http://news.cision.com/viscogel-ab/r/viscogel-ab-reports-positive-results-from-safety-studies,c9225058</link><guid isPermaLink="false">cision457224</guid><description><![CDATA[Viscogel AB today announced a successful completion of the toxicology studies that were carried out within the ViVac-project. The results showed that ViscoGel® was well tolerated even at higher doses and no unexpected effects were observed.
The recent toxicology studies were completed in order to prepare for the planned clinical trial with the company’s vaccine adjuvant, ViscoGel®. The toxicology results were included in the recently submitted regulatory application to start a clinical phase I/II study in Sweden. The clinical trial will evaluate safety and efficacy of ViscoGel® in]]></description><pubDate>Mon, 27 Feb 2012 15:26:44 GMT</pubDate></item><item><title>Results on ViscoGel® adjuvant published in Vaccine</title><link>http://news.cision.com/viscogel-ab/r/results-on-viscogel--adjuvant-published-in-vaccine,c9201025</link><guid isPermaLink="false">cision431687</guid><description><![CDATA[Preclinical results describing the efficacy of ViscoGel® - a novel vaccine adjuvant - were recently published in the peer-reviewed journal Vaccine.  The results support Proof of Concept for ViscoGel® as an effective vaccine adjuvant.
In the published preclinical studies, ViscoGel® was used as an adjuvant together with Act-HIB®, a commercial vaccine against Haemophilus influenzae. ViscoGel® significantly improved the efficacy of the vaccine and induced a strong and sustained immunologic response.

Viscogel’s chitosan-based adjuvant improves the efficacy of vaccine antigens, thus enabling]]></description><pubDate>Mon, 19 Dec 2011 09:46:14 GMT</pubDate></item></channel></rss>